ClinicalTrials.gg
CompletedNCT01239797ELOQUENT - 2Updated Jun 1, 2022Results posted

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

A Phase 3 interventional study of Lenalidomide and Dexamethasone in Lymphoma and Multiple Myeloma, sponsored by Bristol-Myers Squibb. Completed at 216 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-01.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
646
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 44 studies testing dexamethasone in Lymphoma — 4 open to participants now, 8 under way, 1 of them phase 3. Dexamethasone · Lymphoma.

Enrollment
4th of 42
646 · median 48
Started
2011
the only one that year
Phase 3
7 of 44
none open now
Registered
33rd of 44
by date
Lead sponsor
1 of 44
Bristol-Myers Squibb

Among the 44 studies testing dexamethasone in Lymphoma, this one is the 4th largest by enrollment of the 42 interventional ones that give a count, is the only one that started in 2011, is one of 7 in phase 3, and was the 33rd registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

4 of the 44 studies testing dexamethasone in Lymphoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing dexamethasone in Lymphoma, or all of them as a file.
02

Study summary

The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).

03

Conditions studied

  • Lymphoma
  • Multiple Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion criteria

Inclusion Criteria:

  • Documented progression from most recent
  • 1-3 prior lines of therapy
  • ≥3 months
  • Prior treatment with Lenalidomide permitted if:

    1. Best response achieved was ≥Partial Response (PR)
    2. Patient was not
    3. Patient did not discontinue due to a Grade ≥3 related adverse event
    4. Subject did not receive more than 9 cycles of Lenalidomide and had at least 9 months between the last dose of Lenalidomide and progression

Exclusion criteria

Exclusion Criteria:

  • Subjects with non-secretory or oligo-secretory or serum free light-chain only myeloma
  • Active plasma cell leukemia
  • Known (HIV) infection or active hepatitis A, B, or C
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
646 participants (actual)

Study arms

  • Active comparator
    Lenalidomide + Dexamethasone

    Drug: Lenalidomide · Drug: Dexamethasone

  • Experimental
    Lenalidomide + Dexamethasone +Elotuzumab

    Drug: Lenalidomide · Drug: Dexamethasone (Oral) · Drug: Dexamethasone (IV) · Biological: Elotuzumab (BMS-901608; HuLuc63)

Interventions

  • Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug

    Also known as: Revlimid®

  • Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug

    Also known as: Decadron®, Dexamethasone Intensol®, Dexpak®, Taperpak®

  • On weeks without Elotuzumab dosing: Tablets, Oral, 40mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug. On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug

    Also known as: Decadron®, Dexamethasone Intensol®, Dexpak®, Taperpak®

  • On weeks without Elotuzumab dosing: Not Applicable (N/A) On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly, Repeat every 28 days until subject meets criteria for discontinuation of study drug

    Also known as: Decadron®, Dexamethasone Intensol®, Dexpak®, Taperpak®

  • Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug

06

What researchers measure

Primary outcomes

  1. Median Progression Free Survival (PFS)

    Primary definition of Progression-free survival (PFS) defined as the time from randomization to the date of first documented tumor progression or death due to any cause. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (\> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. The primary analysis of PFS was based on the primary definition using the Independent Review Committee (IRC) tumor assessment using the European Group for Blood and Bone Marrow Transplant (EBMT) criteria. Tumor assessments were made every 4 weeks (±1 week) relative to the first dose of study medication.

    Time frame: From randomization up to 326 events (up to approximately 38 months)

  2. Objective Response Rate (ORR)

    Objective response rate (ORR) defined as the percentage of participants with a best response on-study of partial response (PR) or better (stringent CR \[sCR\], complete response \[CR\], very good partial response \[VGPR\], and partial response \[PR\]) based on the Independent Review Committee (IRC) assessment of best response using the European Group for Blood and Bone Marrow Transplant (EBMT) assessment criteria. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (\> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. Assessments were made every 4 weeks.

    Time frame: From randomization up to approximately 38 months

Secondary outcomes

  1. Median Overall Survival (OS)

    Overall survival is defined as the time from randomization to the date of death from any cause. If a subject has not died, their survival time will be censored at the date of last contact ("last known alive date"). A subject will be censored at the date of randomization if they were randomized but had no follow-up. (Based on Kaplan Meier estimates)

    Time frame: Randomization to the date of death from any cause (up to approximately 9 years)

  2. Change From Baseline of Mean Score Pain Severity (BPI-SF)

    The change from baseline of the mean score of pain severity at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 ("No pain", "No interference") to 10 ("Pain as bad as you can imagine", "Highest imaginable interference") numeric rating scale.

    Time frame: From baseline up to approximately 38 months

  3. Change From Baseline of Mean Score Pain Interference (BPI-SF)

    The change from baseline of the mean score of pain interference at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 ("No pain", "No interference") to 10 ("Pain as bad as you can imagine", "Highest imaginable interference") numeric rating scale.

    Time frame: From baseline up to approximately 38 months

07

Results

Posted Jan 5, 2017

Participant flow

Randomized Participants
Participant flow — Randomized Participants
MilestoneLenalidomide + Dexamethasone + ElotuzumabLenalidomide + Dexamethasone
Started321325
Completed319316
Not completed29
Withdrew: Participant no longer meets study criteria11
Withdrew: Participant withdrew consent17
Withdrew: Adverse event unrelated to study drug01
Treated Participants
Participant flow — Treated Participants
MilestoneLenalidomide + Dexamethasone + ElotuzumabLenalidomide + Dexamethasone
Started318317
Completed00
Not completed318317
Withdrew: Disease progression185185
Withdrew: Study drug toxicity3945
Withdrew: Adverse event unrelated to study drug3137
Withdrew: Participants request to discontinue study treatment2818
Withdrew: Administrative reason by sponsor134
Withdrew: Other reasons1414
Withdrew: Participant withdrew consent611
Withdrew: Death11
Withdrew: Participant no longer meets study criteria11
Withdrew: Poor/non-compliance01

Outcome measures

PrimaryMedian Progression Free Survival (PFS)

Primary definition of Progression-free survival (PFS) defined as the time from randomization to the date of first documented tumor progression or death due to any cause. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (\> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. The primary analysis of PFS was based on the primary definition using the Independent Review Committee (IRC) tumor assessment using the European Group for Blood and Bone Marrow Transplant (EBMT) criteria. Tumor assessments were made every 4 weeks (±1 week) relative to the first dose of study medication.

Time frame:
From randomization up to 326 events (up to approximately 38 months)
Reported as:
Median · Months
Median Progression Free Survival (PFS)
MonthsLenalidomide + Dexamethasone + ElotuzumabLenalidomide + Dexamethasone
Median Progression Free Survival (PFS)19.35 (16.62 to 22.18)14.85 (12.09 to 17.22)
Statistical analysis
  • Lenalidomide + Dexamethasone + Elotuzumab vs Lenalidomide + Dexamethasone · Log Rank · p = 0.0014 · Hazard ratio (hr): 0.73 · 95% CI 0.60 to 0.892-sided p-value for stratified log rank test
Post-hocMedian Progression Free Survival (PFS) - Extended Collection

The time from randomization to the date of first documented tumor progression or death due to any cause. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (\> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. Tumor assessments were made every 4 weeks (±1 week) relative to the first dose of study medication based on Independent Review Committee (IRC) tumor assessment using the European Group for Blood and Bone Marrow Transplant (EBMT) criteria. Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 06-Jul-2018)

Time frame:
From randomization up to to the date of first documented tumor progression or death (up to approximately 85 months)
Reported as:
Median · Months
Median Progression Free Survival (PFS) - Extended Collection
MonthsLenalidomide + Dexamethasone + ElotuzumabLenalidomide + Dexamethasone
Median Progression Free Survival (PFS) - Extended Collection19.42 (16.62 to 22.31)14.92 (12.25 to 17.31)
Statistical analysis
  • Lenalidomide + Dexamethasone + Elotuzumab vs Lenalidomide + Dexamethasone · Log Rank · p = 0.0005 · Hazard ratio (hr): 0.72 · 95% CI 0.60 to 0.872-sided p-value for stratified log rank test
PrimaryObjective Response Rate (ORR)

Objective response rate (ORR) defined as the percentage of participants with a best response on-study of partial response (PR) or better (stringent CR \[sCR\], complete response \[CR\], very good partial response \[VGPR\], and partial response \[PR\]) based on the Independent Review Committee (IRC) assessment of best response using the European Group for Blood and Bone Marrow Transplant (EBMT) assessment criteria. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (\> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. Assessments were made every 4 weeks.

Time frame:
From randomization up to approximately 38 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsLenalidomide + Dexamethasone + ElotuzumabLenalidomide + Dexamethasone
Objective Response Rate (ORR)78.5 (73.6 to 82.9)65.5 (60.1 to 70.7)
Statistical analysis
  • Lenalidomide + Dexamethasone + Elotuzumab vs Lenalidomide + Dexamethasone · Cochran-Mantel-Haenszel · p = 0.0002 · Odds ratio (or): 1.95 · 95% CI 1.36 to 2.78Stratified by B2 microglobulin (\<3.5 mg/L vs \>=3.5 mg/L), number of prior lines of therapy (1 vs \>=2), and immunomodulatory drug use at randomization
  • Lenalidomide + Dexamethasone + Elotuzumab vs Lenalidomide + Dexamethasone · Difference in orr: 12.7 · 95% CI 6.2 to 19.3
SecondaryMedian Overall Survival (OS)

Overall survival is defined as the time from randomization to the date of death from any cause. If a subject has not died, their survival time will be censored at the date of last contact ("last known alive date"). A subject will be censored at the date of randomization if they were randomized but had no follow-up. (Based on Kaplan Meier estimates)

Time frame:
Randomization to the date of death from any cause (up to approximately 9 years)
Reported as:
Median · Months
Median Overall Survival (OS)
MonthsLenalidomide + Dexamethasone + ElotuzumabLenalidomide + Dexamethasone
Median Overall Survival (OS)48.30 (40.34 to 51.94)39.62 (33.25 to 45.27)
SecondaryChange From Baseline of Mean Score Pain Severity (BPI-SF)

The change from baseline of the mean score of pain severity at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 ("No pain", "No interference") to 10 ("Pain as bad as you can imagine", "Highest imaginable interference") numeric rating scale.

Time frame:
From baseline up to approximately 38 months
Reported as:
Mean · Score on a scale
Change From Baseline of Mean Score Pain Severity (BPI-SF)
Score on a scaleLenalidomide + Dexamethasone + ElotuzumabLenalidomide + Dexamethasone
Change From Baseline of Mean Score Pain Severity (BPI-SF)0.52 ± 2.237-0.04 ± 2.408
SecondaryChange From Baseline of Mean Score Pain Interference (BPI-SF)

The change from baseline of the mean score of pain interference at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 ("No pain", "No interference") to 10 ("Pain as bad as you can imagine", "Highest imaginable interference") numeric rating scale.

Time frame:
From baseline up to approximately 38 months
Reported as:
Mean · Score on a scale
Change From Baseline of Mean Score Pain Interference (BPI-SF)
Score on a scaleLenalidomide + Dexamethasone + ElotuzumabLenalidomide + Dexamethasone
Change From Baseline of Mean Score Pain Interference (BPI-SF)0.95 ± 2.4660.48 ± 2.868

Adverse events

Collected over From first dose up to 60 days post last dose of study therapy (Up to approximately 9 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide + Dexamethasone + Elotuzumab226/321 (70.4%)238/318 (74.8%)314/318 (98.7%)
Lenalidomide + Dexamethasone249/325 (76.6%)194/317 (61.2%)309/317 (97.5%)
Most frequent serious events
Showing 10 of 390
Most frequent serious events
EventLenalidomide + Dexamethasone + ElotuzumabLenalidomide + Dexamethasone
PneumoniaInfections and infestations56/31840/317
PyrexiaGeneral disorders25/31817/317
Disease progressionGeneral disorders15/31810/317
DiarrhoeaGastrointestinal disorders7/31812/317
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)12/3183/317
AnaemiaBlood and lymphatic system disorders11/3188/317
Respiratory tract infectionInfections and infestations11/3184/317
Acute kidney injuryRenal and urinary disorders11/3188/317
Pulmonary embolismRespiratory, thoracic and mediastinal disorders11/3188/317
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)10/3184/317
Most frequent other events
Showing 10 of 97
Most frequent other events
EventLenalidomide + Dexamethasone + ElotuzumabLenalidomide + Dexamethasone
DiarrhoeaGastrointestinal disorders159/318122/317
FatigueGeneral disorders154/318131/317
NeutropeniaBlood and lymphatic system disorders114/318137/317
AnaemiaBlood and lymphatic system disorders135/318118/317
PyrexiaGeneral disorders121/31874/317
ConstipationGastrointestinal disorders115/31889/317
CoughRespiratory, thoracic and mediastinal disorders109/31862/317
Back painMusculoskeletal and connective tissue disorders105/31897/317
Muscle spasmsMusculoskeletal and connective tissue disorders99/31885/317
ArthralgiaMusculoskeletal and connective tissue disorders98/31863/317

Baseline characteristics

Randomized: all participants randomized to any treatment group

Age, Continuous
Age, Continuous(years)Lenalidomide + Dexamethasone + ElotuzumabLenalidomide + DexamethasoneTotal
Mean66.2 ± 9.3465.3 ± 10.2665.7 ± 9.81
Age, Customized
Age, Customized(Participants)Lenalidomide + Dexamethasone + ElotuzumabLenalidomide + DexamethasoneTotal
< 65 years old134142276
>= 65 and < 75 years old119122241
>= 75 years old6861129
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide + Dexamethasone + ElotuzumabLenalidomide + DexamethasoneTotal
Female129132261
Male192193385
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenalidomide + Dexamethasone + ElotuzumabLenalidomide + DexamethasoneTotal
Hispanic or Latino516
Not Hispanic or Latino283361
Unknown or Not Reported288291579
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lenalidomide + Dexamethasone + ElotuzumabLenalidomide + DexamethasoneTotal
White264280544
Black or African American131023
American Indian or Alaska Native000
Asian333164
Native Hawaiian or Other Pacific Islander101
Other9413
Not Reported101
08

Study locations

216 sites
  • Northwest Alabama Cancer Center, Pc
    Muscle Shoals, Alabama 35661, United States
  • Acrc/Arizona Clinical Research Center, Inc.
    Tucson, Arizona 85715, United States
  • Local Institution
    Berkeley, California 94704, United States
  • Local Institution
    Burbank, California 91505, United States
  • Compassionate Cancer Res Grp
    Corona, California 92879, United States
  • Local Institution
    Corona, California 92879, United States
  • San Diego Pacific Oncology& Hematology Associates, Inc
    Encinitas, California 92024, United States
  • Local Institution
    Greenbrae, California 94904, United States
  • Ucla-Division Of Hematology/Oncology
    Los Angeles, California 90095, United States
  • Medical Oncology Care Associates
    Orange, California 92868, United States
  • Sharp Clinical Oncology Research
    San Diego, California 92123, United States
  • Local Institution
    Vallejo, California 94589, United States
  • Local Institution
    Boca Raton, Florida 33486, United States
  • Cancer Care Centers Of Florida
    Brooksville, Florida 34613, United States
  • Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
  • Local Institution
    New Port Richey, Florida 34652, United States
  • Cancer Institute Of Florida
    Orlando, Florida 32804, United States
  • Local Institution
    Titusville, Florida 32796, United States
  • Florida Cancer Specialists
    West Palm Beach, Florida 33401, United States
  • Winship Cancer Institute.
    Atlanta, Georgia 30322, United States
  • Georgia Health Science University
    Augusta, Georgia 30912, United States
  • Orchard Healthcare Research Inc.
    Skokie, Illinois 60077, United States
  • Local Institution
    Indianapolis, Indiana 46260, United States
  • Local Institution
    Mishawaka, Indiana 46545, United States
  • Local Institution
    Iowa City, Iowa 52242, United States
  • Local Institution
    Lexington, Kentucky 40503, United States
  • Local Institution
    Louisville, Kentucky 40207, United States
  • Pikeville Medical Center
    Pikeville, Kentucky 41501, United States
  • Cancer Center Of Acadiana At Lafayette General
    Lafayette, Louisiana 70503, United States
  • Local Institution
    Shreveport, Louisiana 71101, United States
  • Local Institution
    Shreveport, Louisiana 71103, United States
  • Willis Knighton Cancer Center
    Shreveport, Louisiana 71103, United States
  • Dana Farber Cancer Inst
    Boston, Massachusetts 02215, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Capitol Comprehensive Cancer Care Center
    Jefferson City, Missouri 65101, United States
  • Washington University School Of Medicine
    Saint Louis, Missouri 63110, United States
  • Local Institution
    Springfield, Missouri 65807, United States
  • Local Institution
    Las Vegas, Nevada 89106, United States
  • NYU Clinical Cancer Center
    New York, New York 10016, United States
  • Local Institution
    New York, New York 10019, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Local Institution
    Stony Brook, New York 11794-8151, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • Gaston Hematology & Oncology
    Gastonia, North Carolina 28054, United States
  • Local Institution
    Bismarck, North Dakota 58501, United States
  • University Of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Local Institution
    Tulsa, Oklahoma 74136, United States
  • Local Institution
    Bethlehem, Pennsylvania 18015, United States
  • Western Pennsylvania Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • Local Institution
    Charleston, South Carolina 29414, United States
  • Local Institution
    Greenville, South Carolina 29615, United States
  • Local Institution
    Knoxville, Tennessee 37909, United States
  • The West Clinic
    Memphis, Tennessee 38120, United States
  • Cancer Specialists Of South Texas, Pa
    Corpus Christi, Texas 78412, United States
  • Ut Southwestern Medical Center
    Dallas, Texas 75390-8565, United States
  • University Of Texas Md Anderson Cancer Ctr
    Houston, Texas 77030, United States
  • Northwest Cancer Center
    Houston, Texas 77090, United States
  • Hematology-Oncology Associates Of Fredricksburg, Inc
    Fredericksburg, Virginia 22408, United States
  • Va Puget Sound Health Care System
    Seattle, Washington 98108, United States
  • Gundersen Clinic, Ltd
    La Crosse, Wisconsin 54601, United States
  • University Of Wisconsin Hospital And Clinics
    Madison, Wisconsin 53792, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Local Institution
    Albury, New South Wales 2640, Australia
  • Local Institution
    Canberra, New South Wales 2605, Australia
  • Local Institution
    South Brisbane, Queensland 4101, Australia
  • Local Institution
    Adelaide, South Australia 5000, Australia
  • Local Institution
    Malvern, Victoria 3144, Australia
  • Local Institution
    Melbourne, Victoria 3004, Australia
  • Local Institution
    Nedlands, Western Australia 6009, Australia
  • Local Institution
    Murdoch, 6150, Australia
  • Local Institution
    Rankweil, 6830, Austria
  • Local Institution
    Steyr, 4400, Austria
  • Local Institution
    Wels, 4600, Austria
  • Local Institution
    Wien, 1220, Austria
  • Local Institution
    Antwerpen, 2060, Belgium
  • Local Institution
    Brussels, 1000, Belgium
  • Local Institution
    Brussels, 1020, Belgium
  • Local Institution
    Brussels, 1090, Belgium
  • Local Institution
    Brussles, 1200, Belgium
  • Local Institution
    Edegem-antwerp, 2650, Belgium
  • Local Institution
    Liege, 4000, Belgium
  • Local Institution
    Yvoir, 5530, Belgium
  • Local Institution
    Calgary, Alberta T2N 4N2, Canada
  • Local Institution
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Local Institution
    London, Ontario N6A 4G5, Canada
  • Local Institution
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution
    Montreal, Quebec H4J 1C5, Canada
  • Local Institution
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Local Institution
    Barrie, L4M 6M2, Canada
  • Local Institution
    Montreal, H4A 3J1, Canada
  • Local Institution
    Brno, 625 00, Czechia
  • Local Institution
    Hradec Kralove, 500 05, Czechia
  • Local Institution
    Praha 10, 100 34, Czechia
  • Local Institution
    Praha 2, 128 08, Czechia
  • Local Institution
    Copenhagen, 2100, Denmark
  • Local Institution
    Odense C, 5000, Denmark
  • Local Institution
    Vejle, 7100, Denmark
  • Local Institution
    Blois, 41016, France

Showing the first 100 of 216 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018 Oct 15;124(20):4032-4043. doi: 10.1002/cncr.31680. Epub 2018 Sep 11. PubMed 30204239 ↗
  • Passey C, Mora J, Dodge R, Gibiansky L, Sheng J, Roy A, Bello A, Gupta M. An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab. AAPS J. 2017 Mar;19(2):557-567. doi: 10.1208/s12248-016-0033-9. Epub 2017 Jan 9. PubMed 28070715 ↗
  • Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Rollig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2. PubMed 26035255 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2011 to primary completion in Sep 2014, 38 months.

Results were first posted in Jan 2017, 2 years 4 months after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 69. This study's 38 months is below that.

Counting every sponsor, half of 62 studies reached it within 67 months; a quarter within 52 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2010
First posted
Nov 11, 2010
StartActual
Jun 20, 2011
Primary completionActual
Sep 2, 2014
CompletionActual
Apr 21, 2021
Results first posted
Jan 5, 2017
Last update
Jun 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01239797
Collaborators
AbbVie
Responsible party
Sponsor
First posted
Nov 11, 2010
Start date
Jun 20, 2011
Primary completion
Sep 2, 2014
Completion
Apr 21, 2021
Results posted
Jan 5, 2017
Last update
Jun 1, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexamethasone · Elotuzumab

Start the discussion